Cancer Library VCC
@VCCLibrary
The only cancer specialist library service in Wales. Supporting NHS and academic staff, students and health professionals throughout the Principality.
🚨 New Episode Out Now! 🎧 💉Subcutaneous Immunotherapy – What are the logisitics? 🏥💉 In Episode 152, the Immunobuddies are back with Jo Parkes @jpar088 and Dr Vasiliki Michalarea to tackle the real-world logistics of rolling out subcutaneous immunotherapy in clinical…
We’re pleased to announce the publication of our latest Annual Report. Find out how we’ve made an impact in 2024/25 here: healthtechnology.wales/wp-content/upl…
"We believe that our searches should be researcher-led & AI empowered, & not AI-led." Lots of potential. Will novice searchers think LLMs can undertake comprehensive literature searches for a #SystematicReview & use them uncritically? @Anne_InfoSpec @YHEC1 sites.google.com/york.ac.uk/yhe…
🎉 We are delighted to share that, as of June 2025, the Velindre @ Nevill Hall Radiotherapy Unit is open and operational - increasing our service's capacity to deliver radiotherapy treatments by 20%. 📽 youtu.be/D7R4dWgftaQ
🎧 NEW EPISODE OUT NOW! Is Subcutaneous Immunotherapy a Game-Changer or Just Hype? 💉🤔 Join @RickyFrazer1 & @AOlssonBrown as they unpack the science, promise & pitfalls of Subcutaneous Immunotherapy with special guests Jo Parkes & Dr Vasiliki Michalarea. We’re diving into:…
Derivation and validation of the AJCC9V pathological stage classification for HPV-positive oropharyngeal carcinoma: a multicentre registry analysis sciencedirect.com/science/articl… #Cancer @VelindreCS
Adult Cancer #Pain, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology jnccn.org/view/journals/… #Cancer
NCCN Guidelines Insights: Thyroid Carcinoma, Version 1.2025 jnccn.org/view/journals/… #Cancer
Reirradiation dose constraints in clinical practice: Results of an international survey sciencedirect.com/science/articl… #Cancer
Real-life data on tebentafusp in metastatic uveal #melanoma patients from four EURACAN Expert Centres sciencedirect.com/science/articl…
Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB–D/IV #melanoma treated with adjuvant immunotherapy: CheckMate 915 jitc.bmj.com/content/13/7/e…
Randomized phase II study of consolidation immunotherapy with nivolumab & ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell #lungcancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081 jitc.bmj.com/content/13/7/e…
Addendum 1: Society for Immunotherapy of #Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of #lungcancer and mesothelioma jitc.bmj.com/content/13/7/e…
Risk Factors for COVID-19–Related Hospitalization and Death in Patients With #Cancer: The National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS) jamanetwork.com/journals/jamao…
Early-Onset Gastrointestinal Cancers: A Review jamanetwork.com/journals/jama/… #Cancer
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple #myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial sciencedirect.com/science/articl… #cancer
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant #prostatecancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial sciencedirect.com/science/articl…
Talazoparib plus enzalutamide in men with metastatic castration-resistant #prostatecancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial sciencedirect.com/science/articl…
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous #OvarianCancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201 ascopubs.org/doi/10.1200/JC…
Therapy for Stage IV Non–Small Cell #LungCancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1 ascopubs.org/doi/10.1200/JC…